Annovis Bio earnings release, August 14, 2026
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
Malvern, PA, August 14, 2026 -- Annovis Bio, Inc. (NYSE:
ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the second quarter ended June 30, 2026.
“Our company witnessed major clinical strides during the second quarter,” said Maria Maccecchini, Ph.D., President and CEO of Annovis. “We reached an important milestone – full enrollment of our pivotal Phase 3 study in early AD – having recruited 850 patients. This number tells us how urgently patients and families need new options and underscores their faith in our approach to treating AD. We also plan to continue the ongoing study with an open-label extension (OLE) so AD patients can continue buntanetap treatment after finishing the trial. With topline data on track for early 2027, our team has already begun preparing for regulatory submission so that we are ready to move once the results are in hand.”
Clinical highlights
Alzheimer’s disease – pivotal Phase 3 trial
Alzheimer’s disease – OLE study
Parkinson’s disease – OLE study
Corporate highlights
Upcoming milestones
Financial results
About
Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on
LinkedIn, YouTube, and
X.
Investor
Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking
Statements
Financial statements
Income Statement
Three Months Ended — ANNOVIS BIO, INC. Statement of Operations (Unaudited)
| Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Six Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2025 | ||
|---|---|---|---|---|---|
| Operating expenses: | Research and development | 12,007,300 | 5,161,921 | 28,727,663 | 10,173,438 |
| Operating expenses: | General and administrative | 2,370,412 | 1,109,532 | 3,662,232 | 2,380,696 |
| Operating expenses: | Total operating expenses | 14,377,712 | 6,271,453 | 32,389,895 | 12,554,134 |
| Operating expenses: | Operating loss | -14,377,712 | -6,271,453 | -32,389,895 | -12,554,134 |
| Other income: | Interest income | 160,233 | 191,395 | 298,033 | 379,007 |
| Other income: | Other financing costs (Note 7) | -1,589,336 | -1,589,336 | ||
| Other income: | Change in fair value of warrants (Note 7) | 986,000 | -140,000 | 1,254,000 | 418,000 |
| Other income: | Total other income, net | -443,103 | 51,395 | -37,303 | 797,007 |
| Other income: | Net loss | -14,820,815 | -6,220,058 | -32,427,198 | -11,757,127 |
| Net loss per share (Note 9) | Basic | -0.4 | -0.32 | -0.99 | -0.64 |
| Net loss per share (Note 9) | Diluted | -0.4 | -0.32 | -0.99 | -0.64 |
| Weighted-average number of common shares used in computing net loss per share | Basic | 37,518,778 | 19,486,231 | 32,710,046 | 18,464,877 |
| Weighted-average number of common shares used in computing net loss per share | Diluted | 37,518,778 | 19,486,231 | 32,710,046 | 18,464,877 |
Balance Sheet
ANNOVIS BIO, INC. Balance Sheets
| June 30, – 2026 – (Unaudited) | December 31, – 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 18,728,945 | 19,532,338 |
| Current assets: | Prepaid expenses and other current assets | 3,308,146 | 1,549,287 |
| Current assets: | Total assets | 22,037,091 | 21,081,625 |
| Current liabilities: | Accounts payable | 3,327,138 | 2,590,516 |
| Current liabilities: | Accrued expenses | 3,031,572 | 1,044,859 |
| Current liabilities: | Total current liabilities | 6,358,710 | 3,635,375 |
| Non-current liabilities: | Warrant liability | 19,933,000 | 595,000 |
| Non-current liabilities: | Total liabilities | 26,291,710 | 4,230,375 |
| Stockholders’ equity: | Common stock - $0.0001 par value, 70,000,000 shares authorized, 42,606,152 and 27,199,139 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 4,260 | 2,719 |
| Stockholders’ equity: | Additional paid-in capital | 191,871,978 | 180,552,190 |
| Stockholders’ equity: | Accumulated deficit | -196,130,857 | -163,703,659 |
| Stockholders’ equity: | Total stockholders’ equity | -4,254,619 | 16,851,250 |
| Stockholders’ equity: | Total liabilities and stockholders’ equity | 22,037,091 | 21,081,625 |
Full release
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange
Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s
SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact
Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355 www.annovisbio.com
Investor
Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio ir@annovisbio.com
(Tables to follow)
ANNOVIS BIO, INC.
Balance Sheets
ANNOVIS BIO, INC.
Statement of Operations
(Unaudited)